Abstract
The prognosis for children with diffuse intrinsic pontine gliomas (DIPGs) is dismal. Although DIPGs constitute only 10–15 % of all pediatric brain tumors, they are the main cause of death in this group with a median survival of less than 12 months. Standard therapy involves radiotherapy, which produces transient neurologic improvement. Despite several clinical trials having been conducted, including trials on targeted agents to assess their efficacy, there is no clear improvement in prognosis. However, knowledge of DIPG biology is increasing, mainly as a result of research using biopsy and autopsy samples. In this review, we discuss recent studies in which systemic therapy was administered prior to, concomitantly with, or after radiotherapy. The discussion also includes novel therapeutic options in DIPG. Continuing multimodal and multitargeted therapies might lead to an improvement in the dismal prognosis of the disease.
Similar content being viewed by others
References
Fleming AJ, Chi SN. Brain tumors in children. Curr Probl Pediatr Adolesc Health Care. 2012;42:80–103.
Crocetti E, Trama A, Stiller C, et al. Epidemiology of glial and non-glial brain tumors in Europe. Eur J Cancer. 2012;48:1532–42.
Choux M, Lena G, Do L. Brainstem tumors. In: Choux M, Di Rocco C, Hockley A, editors. Pediatric neurosurgery. New York: Churchill Livingstone; 2000. p. 471–91.
Freeman CR, Farmer JP. Pediatric brain stem gliomas: a review. Int J Radiat Phys. 1998;40:265–71.
Hargrave D, Bartels U, Bouffet E. Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol. 2006;7:241–8.
Jennings MT, Freeman ML, Murray MJ. Strategies in the treatment of diffuse pontine gliomas: the therapeutic role of hyperfractionated radiotherapy and chemotherapy. J Neurooncol. 1996;28:207–22.
Jennings M, Spotso R, Boyett JM, et al. Preradiation chemotherapy in primary high-risk brainstem tumors: phase II study CCG-9941 of the Children’s Cancer Group. J Clin Oncol. 2002;20:3431–7.
Kretschmar CS, Tarbell NJ, Barnes PD, et al. Pre-irradiation chemotherapy and hyperfractionated radiation therapy 66 Gy for children with brain stem tumors: a phase II study of the Pediatric Oncology Group, Protocol 8833. Cancer. 1993;72:1404–13.
Dunkel IJ, Garvin JH Jr, Goldman S, et al. High dose chemotherapy with autologous bone marrow rescue for children with diffuse pontine brain stem tumors. Children’s Cancer Group. J Neurooncol. 1998;37:67–73.
Frappaz D, Schell M, Thiesse P, et al. Preradiation chemotherapy may improve survival in pediatric diffuse intrinsic brainstem gliomas: final results of BSG 98 prospective trial. Neuro Oncol. 2008;10(4):599–607.
Massimino M, Spreafico F, Biassoni V, et al. Diffuse pontine gliomas in children: changing strategies, changing results? A mono-institutional 20-year experience. J Neurooncol. 2008;87:355–61.
Grundy RG, Wilne SH, Robinson KJ, et al. Primary postoperative chemotherapy without radiotherapy for treatment of brain tumours other than ependymoma in children under 3 years: results of the first UKCCSG/SIOP CNS 9204 trial. Eur J Cancer. 2010;46(1):120–33.
Wolff JE, Kortmann RD, Wolff B, et al. High dose methotrexate for pediatric high grade glioma—results of the HIT-GBM-D Pilot study. J Neurooncol. 2011;102:433–42.
Doz F, Neuenschwander S, Bouffet E, Gentet JC, Schneider P, Kalifa C, et al. Carboplatin before and during radiation therapy for the treatment of malignant brain stem tumours: a study by the Société Française d’Oncologie Pédiatrique. Eur J Cancer. 2002;38:815–9.
Bernier-Chastagner V, Grill J, Doz F, et al. Topotecan as a radiosensitizer in the treatment of children with malignant diffuse brainstem gliomas: results of a French Society of Paediatric Oncology phase II study. Cancer. 2005;104:2792–7.
Packer RJ, Krailo M, Mehta M, et al. Phase 1 study of concurrent RMP-7 and carboplatin with radiotherapy for children with newly diagnosed brainstem gliomas. Cancer. 2005;104:1281–7.
Wolff JE, Westphal S, Molenkamp G, et al. Treatment of paediatric pontine glioma with oral trophosphamide and etoposide. Br J Cancer. 2002;87:945–9.
Wolff JE, Wagner S, Reinert C, et al. Maintenance treatment with interferon-gamma and low dose cyclophosphamide for pediatric high-grade glioma. J Neurooncol. 2006;79(3):315–21.
Wolff JE, Driever PH, Erdlenbruch B, et al. Intensive chemotherapy improves survival in pediatric high-grade glioma after gross total resection: results of the HIT-GBM-C protocol. Cancer. 2010;116(3):705–12.
Wagner S, Warmuth-Metz M, Emser A, et al. Treatment options in childhood pontine gliomas. J Neurooncol. 2006;79:281–7.
Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.
Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol. 2010;28:2051–7.
Broniscer A, Iacono L, Chintagumpala M, et al. Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98). Cancer. 2005;103:133–9.
Lashford LS, Thiesse P, Jouvet A, et al. Temozolomide in malignant gliomas of childhood: a United Kingdom Children’s Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. J Clin Oncol. 2002;20:4684–91.
Jalali R, Raut N, Arora B, et al. Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. Int J Radiat Oncol Biol Phys. 2010;77:113–8.
Chiang KL, Chang KP, Lee YY, et al. Role of temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: experience at a single institution. Childs Nerv Syst. 2010;26:1035–41.
Kim CY, Kim SK, Phi JH, et al. A prospective study of temozolomide plus thalidomide during and after radiation therapy for pediatric diffuse pontine gliomas: preliminary results of the Korean Society for Pediatric Neuro-Oncology study. J Neurooncol. 2010;100:193–8.
Chassot A, Canale S, Varlet P, et al. Radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. J Neurooncol. 2012;106:399–407.
Cohen K, Heideman R, Zhou T, et al. Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children’s Oncology Group. Neuro Oncol. 2011;4:410–6.
Paugh BS, Qu C, Jones C, et al. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol. 2010;28(18):3061–8.
Zarghooni M, Bartels U, Lee E, et al. Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. J Clin Oncol. 2010;28(8):1337–44.
Sirachainan N, Pakakasama S, Visudithbhan A, et al. Concurrent radiotherapy with temozolomide followed by adjuvant temozolomide and cis-retinoic acid in children with diffuse intrinsic pontine glioma. Neuro Oncol. 2008;10:577–82.
Kebudi R, Cakir FB, Yaman Agaoglu F, et al. Pediatric diffuse intrinsic pontine glioma patients from a single center. Childs Nerv Syst. 2013;29(4):583–8.
Narayana A, Kunnakkat S, Chacko-Mathew J, et al. Bevacizumab in recurrent high-grade pediatric gliomas. Neuro Oncol. 2010;12:985–90.
Gururangan S, Chi SN, Young Poussaint T, et al. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. J Clin Oncol. 2010;28:3069–75.
Stockhammer G. Avastin/irinotecan in patients with recurrent or progressive malignant glioma (AVIRMA01-09). ClinicalTrials.gov identifier NCT01144988. http://clinicaltrials.gov/ct2/show/NCT01144988?term=NCT01144988&rank=1. Accessed May 16 2013.
Cruz O, de Torres C, Suñol M, Salvador H, Lopez E, Cardesa T, et al. Multimodal therapy for diffuse intrinsic pontine gliomas including nimotuzumab and bevacizumab [abstract no. DIPG.08]. Neuro Oncol. 2010;12(6):ii10.
Kieran MW. Molecularly determined treatment of diffuse intrinsic pontine gliomas (DIPG). ClinicalTrials.gov identifier NCT01182350. http://clinicaltrials.gov/ct2/show/NCT01182350?term=NCT01182350&rank=1. Accessed May 16 2013.
Turner CD, Chi S, Marcus KJ, et al. Phase II study of thalidomide and radiation in children with newly diagnosed brain stem gliomas and glioblastoma multiforme. J Neurooncol. 2007;82:95–101.
Kivivuori SM, Riikonen P, Valanne L, Lonnqvist T, Saarinen-Pihkala UM. Antiangiogenic combination therapy after local radiotherapy with topotecan radiosensitizer improved quality of life for children with inoperable brainstem gliomas. Acta Paediatr. 2011;100(1):134–8.
Pediatric Brain Tumor Consortium. Enzastaurin in treating young patients with refractory primary CNS tumors. ClinicalTrials.gov identifier NCT00503724. http://clinicaltrials.gov/ct2/show/NCT00503724. Accessed 30 Sep 2010.
Pediatric Brain Tumor Consortium, National Cancer Institute. AZD2171 in treating young patients with recurrent, progressive, or refractory primary CNS tumors. ClinicalTrials.gov identifier NCT00326664. http://clinicaltrials.gov/ct2/show/NCT00326664?term=PBTC-020&rank=1. Accessed 25 Jan 2011.
Gilbertson RJ, Ashley H, Herman R, et al. ERBB1 is amplified and overexpressed in high-grade diffusely infiltrative pediatric brain stem glioma. Clin Can Res. 2003;9:3620–4.
Bode U, Buchen S, Warmuth-Metz M, Pietsch T, Bach F, Fleischhack G. Final report of a phase II trial of nimotuzumab in the treatment of refractory and relapsed high-grade gliomas in children and adolescents [abstract]. J Clin Oncol 2007; 25(Suppl. 2006).
Massimino M, Bode U, Biassoni V, Fleischhack G. Nimotuzumab for pediatric diffuse intrinsic pontine gliomas. Expert Opin Biol Ther. 2011;11(2):247–56.
Massimino M, Biassoni V, Gandola L, et al. Nimotuzumab and vinorelbine concomitantly to radiation and as maintenance for diffuse pontine glioma in childhood: promising results on a series of 20 patients [abstract no. PG-04]. Pediatr Blood Cancer. 2012;59:1004.
Broniscer A, Baker SJ, Stewart CF, et al. Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma. Clin Cancer Res. 2009;15:701–7.
Geoerger B, Hargrave D, Thomas F, et al. ITCC (Innovative Therapies for Children with Cancer) European Consortium. Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. Neuro Oncol. 2011;13(1):109–18.
Geyer JR, Stewart CF, Kocak M, et al. A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas. Eur J Cancer. 2010;46(18):3287–93.
Pollack IF, Stewart CF, Kocak M, et al. A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium. Neuro Oncol. 2011;13(3):290–7.
Broniscer A, Baker JN, Tagen M, et al. Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma. J Clin Oncol. 2010;28(31):4762–8.
Broniscer A. Clinical trial evaluating the combination of vandetanib and dasatinib during and after radiation therapy (RT) in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG). ClinicalTrials.gov identifier NCT00996723. http://clinicaltrials.gov/ct2/show/NCT00996723?term=NCT00996723&rank=1. Accessed May 16 2013.
Memorial Sloan-Kettering Cancer Center. External beam radiation therapy and cetuximab followed by irinotecan and cetuximab for children and young adults with newly diagnosed diffuse pontine tumors and high-grade astrocytomas (POE08-01). ClinicalTrials.gov identifier NCT01012609. http://clinicaltrials.gov/ct2/show/NCT01012609. Accessed 30 Sep 2010.
Pollack IF, Jakacki RI, Blaney SM, et al. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro Oncol. 2007;9:145–60.
Haas-Kogan DA, Banerjee A, Poussaint TY, et al. Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas. Neuro Oncol. 2011;13(3):298–306.
Chaponis D, Barnes JW, Dellagatta JL, et al. Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas. J Neurooncol. 2011;104(1):179–89.
Insys Therapeutics Inc. The PRECISE trial: study of IL13-PE38QQR compared to GLIADEL wafer in patients with recurrent glioblastoma multiforme. ClinicalTrials.gov identifier NCT00076986. http://clinicaltrials.gov/ct2/show/NCT00076986?term=NCT00076986&rank=1. Accessed May 16 2013.
Lonser RR, Warren KE, Butman JA, et al. Real-time image-guided direct convective perfusion of intrinsic brainstem lesions. Technical note. J Neurosurg. 2007;107(1):190–7.
Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10:9–22.
Stupp R, Hegi ME, Neyns B, et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010;28:2712–8.
MacDonald TJ, Stewart CF, Kocak M, et al. Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium study PBTC-012. J Clin Oncol. 2008;26:919–24.
Liau LM, Prins RM, Kiertscher SM, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res. 2005;11:5515–25.
Ardon H, De Vleeschouwer S, Van Calenbergh F, et al. Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours. Pediatr Blood Cancer. 2010;54:519–25.
Phuphanich S. Immunotherapy for patients with brain stem glioma and glioblastoma. ClinicalTrials.gov identifier NCT00576641. http://clinicaltrials.gov/ct2/show/NCT00576641?term=NCT00576641&rank=1. Accessed May 16 2013.
Masoudi A, Elopre M, Amini E, et al. Influence of valproic acid on outcome of high-grade gliomas in children. Anticancer Res. 2008;28:2437–42.
Felix FH, Trompieri NM, de Araujo OL, et al. Potential role for valproate in the treatment of high-risk brain tumors of childhood-results from a retrospective observational cohort study. Pediatr Hematol Oncol. 2011;28(7):556–70.
Children’s Oncology Group, National Cancer Institute. Vorinostat and radiation therapy followed by maintenance therapy with vorinostat in treating younger patients with newly diagnosed pontine glioma. ClinicalTrials.gov identifier NCT01189266. http://clinicaltrials.gov/ct2/show/NCT01189266?term=vorinostat&rank=83. Accessed 30 Sep 2010.
Lee EQ, Puduvalli VK, Reid JM, et al. Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04–03. Clin Cancer Res. 2012;18(21):6032–9.
Zeng WF, Navaratne K, Prayson RA, et al. Aurora B expression correlates with aggressive behaviour in glioblastoma multiforme. J Clin Pathol. 2007;60:218–21.
Cheung CH, Coumar MS, Hsieh HP, et al. Aurora kinase inhibitors in preclinical and clinical testing. Expert Opin Investig Drugs. 2009;18:379–98.
Dar AA, Goff LW, Majid S, et al. Aurora kinase inhibitors: rising stars in cancer therapeutics? Mol Cancer Ther. 2010;9:268–78.
Buczkowicz P, Zarghooni M, Bartels U, et al. Aurora kinase B is a potential therapeutic target in pediatric diffuse intrinsic pontine glioma. Brain Pathol. 2013;23(3):244–53.
Purow BW, Haque RM, Noel MW, et al. Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res. 2005;65(6):2353–63.
Fouladi M, Stewart CF, Olson J, et al. Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study. J Clin Oncol. 2011;29(26):3529–34.
Pediatric Brain Tumor Consortium, National Cancer Institute. ABT-888 and temozolomide in treating young patients with recurrent or refractory CNS tumors. http://www.clinicaltrials.gov/ct2/show/NCT00946335?term=PBTC-027&rank=1. Accessed 25 Jan 2011.
Barth RF, Vicente M, Harling OK, et al. Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer. Radiat Oncol. 2012;7(146):1–21.
Sköld K, Gorlia T, Pellettieri L, et al. Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: an assessment of clinical potential. Br J Radiol. 2010;83(991):596–603.
Diaz AZ. Assessment of the results from the phase I/II boron neutron capture therapy trials at the Brookhaven National Laboratory from a clinician’s point of view. J Neurooncol. 2003;62(1–2):101–9.
Nakagawa Y, Kageji T, Mizobuchi Y, Kumada H, Nakagawa Y. Clinical results of BNCT for malignant brain tumors in children. Appl Radiat Isot. 2009;67(7–8 Suppl):S27–30.
Wolff JE, Rytting ME, Vats TS, et al. Treatment of recurrent diffuse intrinsic pontine glioma: the MD Anderson Cancer Center experience. J Neurooncol. 2012;106:391–7.
Jenkin RD, Boesel C, Ertel I, et al. Brain-stem tumors in childhood: a prospective randomized trial of irradiation with and without adjuvant CCNU, VCR, and prednisone. A report of the Childrens Cancer Study Group. J Neurosurg. 1987;66:227–33.
Jakacki RI, Jamison C, Mathews VP, et al. Dose-intensification of procarbazine, CCNU (lomustine), vincristine (PCV) with peripheral blood stem cell support in young patients with gliomas. Med Pediatr Oncol. 1998;31:483–90.
Walter AW, Gajjar A, Ochs JS, et al. Carboplatin and etoposide with hyperfractionated radiotherapy in children with newly diagnosed diffuse pontine gliomas: a phase I/II study. Med Pediatr Oncol. 1998;30:28–33.
Allen J, Siffert J, Donahue B, et al. A phase I/II study of carboplatin combined with hyperfractionated radiotherapy for brainstem gliomas. Cancer. 1999;86:1064–9.
Bouffet E, Raquin M, Doz F, et al. Radiotherapy followed by high dose busulfan and thiotepa: a prospective assessment of high dose chemotherapy in children with diffuse pontine gliomas. Cancer. 2000;88:685–92.
Korones DN, Fisher PG, Kretschmar C, et al. Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy, vincristine and oral VP-16: a Children’s Oncology Group phase II study. Pediatr Blood Cancer. 2008;50(2):227–30.
Michalski A, Bouffet E, Taylor RE, et al. The addition of high-dose tamoxifen to standard radiotherapy does not improve the survival of patients with diffuse intrinsic pontine glioma. J Neurooncol. 2010;100(1):81–8.
Acknowledgments
No sources of funding were used to assist in the preparation of this review. Rejin Kebudi and Fatma Betul Cakir have no conflicts of interest that are directly relevant to the content of this review.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kebudi, R., Cakir, F.B. Management of Diffuse Pontine Gliomas in Children: Recent Developments. Pediatr Drugs 15, 351–362 (2013). https://doi.org/10.1007/s40272-013-0033-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40272-013-0033-5